🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 77 of 857 · Phase 3 first, then by program name

  1. Glecaprevir/Pibrentasvir

    AbbVie

    Hepatitis C Virus (HCV)

    phase 3 small molecule completed

    2 trials

  2. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  3. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short bowel syndrome

    phase 3 small molecule active

    1 trial

  4. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  5. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  6. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  7. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  8. Glucose 5% 50 ml

    Disc Medicine

    Apnea of prematurity

    phase 3 small molecule active

    1 trial

  9. Glycerin Suppository

    United Therapeutics Europe Ltd

    Encopresis

    phase 3 small molecule completed

    1 trial

  10. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  11. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  12. Gonal-F

    The First People's Hospital of Lianyungang

    Anovulation

    phase 3 mab completed

    1 trial

  13. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  14. Granules for oral suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Niemann-Pick disease type C

    phase 3 small molecule active

    1 trial

  15. Granulocyte Colony-Stimulating Factor(G-CSF)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myelodysplastic Syndrome

    phase 3 small molecule active

    2 trials

  16. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

  17. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  18. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  19. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  20. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  21. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  22. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  23. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources